The opportunities and challenges of personalized genome-based molecular therapies for cancer: Targets, technologies, and molecular chaperones

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 52, Issue 1, 2003, Pages

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Gefitinib; HSP90 molecular chaperone inhibitors; Imatinib; Molecular pathology and genomics of cancer; New molecular targets; Technologies for drug discovery and development; Trastuzumab

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATASE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN RECEPTOR; FLAVOPIRIDOL; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P53; RADICICOL; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ROSCOVITINE; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; COMBINATORIAL CHEMISTRY; CONFERENCE PAPER; DRUG DESIGN; DRUG TARGETING; GENOMICS; HUMAN; HUMAN GENOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; GENE TARGETING; GENOME, HUMAN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS;

EID: 0042326165     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Aherne GW, McDonald E, Workman P (2002) Finding the needle in the haystack: why high-throughput screening is good for your health. Breast Cancer Res 4:148
2. Alaimo PJ, Shogren-Knaak MA, Shokat KM (2001) Chemical genetic approaches for the elucidation of signaling pathways. Curr Opin Chem Biol 5:360
3. Atkins JH, Gershell LJ (2002) Selective anticancer drugs. Nat Rev Drug Discov 1:491
4. Banerji U, O'Donnell A, Scurr M, Benson C, Hanwell J, Clark S, Raynaud F, Turner A, Walton M, Workman P, Judson I (2001) Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc Am Soc Clin Oncol Abstract 326
5. Carr R, Jhoti H (2002) Structure-based screening of low-affinity compounds. Drug Discov Today 7:522
6. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N (2001) A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8:289
7. Chung Y-L, Troy H, Banerji U, Judson IR, Leach MO, Stubbs M, Ronen S, Workman P, Griffiths JR (2002) The pharmacodynamic effects of 17-AAG on HT29 xenografts in mice monitored by magnetic resonance spectroscopy. Proc Am Assoc Cancer Res Abstract 371
8. Clarke PA, Hostein I, Banerji U, Di Stefano F, Maloney A, Walton M, Judson I, Workman P (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19:4125
9. Clarke PA, te Poele R, Wooster R, Workman P (2001) Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 62:1311
10. Couzin J (2002) Cancer drugs: smart weapons prove tough to design. Science 298:522
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949
12. de Bono JS, Rowinsky EK (2002) The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med [Suppl] 8:S19
13. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342
14. Giaconne G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, Rennie P, Ochs J, Averbuch S, Fandi A (2002) A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1) (abstract 40). Ann Oncol 13 [Suppl 5]:2
15. Gullier F, Orain D, Bradley M (2000) Linkers and cleavage strategies in solid-phase organic synthesis and combinatorial chemistry. Chem Rev 100:2091
16. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57
17. Hostein I, Robertson D, Di Stefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003
18. International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human genome. Nature 409:860
19. Johnson DH, Herbst R, Giaconne G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbuch S, Grous J (2002) ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2) (abstract 468O). Ann Oncol 13 [Suppl 5]:127
20. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino-17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940
21. Leach AR, Hann MM (2000) The in silico world of virtual libraries. Drug Discov Today 5:326
22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3
23. Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO (2002) Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 87:783
24. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2:3
25. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181
26. Marx J (2002) Debate surges over the origins of genomic defects in cancer. Science 297:544
27. Mills GB, Lu Y, Kohn EC (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3 K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 98:10031
28. Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 7:2228
29. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55
30. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, Millson SH, Clarke PA, Naaby-Hansen S, Stein R, Cramer R, Mollapour M, Workman P, Piper PW, Pearl LH, Prodromou C (2002) Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Ahal. Mol Cell 10:1307
31. Ponder BA (2001) Cancer genetics. Nature 411:336
32. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65
33. Raynaud FI, Goddard P, Fischer P, McClue S, Workman P (2001) Cassette dosing pharmacokinetics for 107 analogues of the trisubstituted CDK2 inhibitor roscovitine. Proc Am Assoc Cancer Res Abstract 2056
34. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260
35. Rutherford SL, Lindquist S (1998) Hsp90 as a capacitor for morphological evolution. Nature 396:336
36. Schreiber SL (2000) Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964
37. Stockwell BR, Haggarty SJ, Schreiber SL (1999) High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem Biol 6:71
38. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, et al (2001) The sequence of the human genome. Science 291:1304
39. Vogelstein B, Kinzler K (1993). The multistep nature of cancer. Trends Genet 9:138
40. Weinstein IB (2002) Cancer: addiction to oncogenes - the Achilles heal of cancer. Science 297:63
41. Weinstein JN (2002) 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr Opin Pharmacol 2:361
42. Wooster R (2001) Richard Wooster on cancer and the Human Genome Project. Lancet Oncol 2:176
43. Workman P (2000) Cancer - 21st century solutions. Biotech Invest Today 1:28
44. Workman P (2001) Scoring a bull's-eye against cancer genome targets. Curr Opin Pharmacol 1:342
45. Workman P (2002) The impact of genomic and proteomic technologies on the development of new cancer drugs. Ann Oncol 13 [Suppl 4]:115
46. Workman P (2002) Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38:2189
47. Workman P (2002) Cancer genome targets: RAF-ing up tumour cells to overcome oncogene addiction. Expert Rev Anticancer Ther 2:611
48. Workman P (2003) How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des (in press)
49. Workman P, Kaye SB (eds) (2002) A Trends Guide to Cancer Therapeutics. Trends Mol Med [Suppl] 8